New Chief Strategy Officer at XO Life: Dr. Jochen Hurlebaus to lead international expansion
Munich, Germany, 06. August 2024 – XO Life, a leading digital health startup headquartered in Germany that is redefining digital product and therapy guidance for patients with its ImpactMonitor™ meta-platform, announces the appointment of Dr. Jochen Hurlebaus as its new Chief Strategy Officer and VP Client Partnerships. Dr. Hurlebaus, who previously served as Global Head of Digital Health Innovation at Roche Diagnostics, will drive the international expansion of the ImpactMonitor™ platform and build strategic partnerships with multinational companies and key healthcare organizations from 01.08.2024.
About Dr. Jochen Hurlebaus
In his new role at XO Life, Dr. Jochen Hurlebau will lead strategic initiatives to accelerate the company's global expansion and broaden its product and service portfolio. The focus will be on strengthening the international business and forging new strategic alliances.
Dr. Hurlebaus holds a PhD in mathematics and bioinformatics and an Executive MBA from ESSEC Paris and Mannheim Business School. He has over 20 years of experience in the healthcare sector, of which he has worked in digital health for the past eight years. Before joining XO Life, Dr. Jochen Hurlebaus headed the global digital health innovation department at Roche Diagnostics. In various roles, he was responsible for numerous innovation projects for telemedical patient care, which brought significant benefits for patients and formed the basis for the development of new business models. His visionary leadership led to the creation and growth of Startup Creasphere, a global innovation program that has enabled successful co-creation projects with nearly 100 digital health startups worldwide.
"XO Life's platform approach of uniting all patients, healthcare professionals and manufacturers on a single platform has enormous potential to revolutionize an entire industry that has been struggling for years with challenges such as lack of patient access, insufficient patient education, lack of adherence and isolated data sources," explains Dr. Jochen Hurlebaus. "For patients, digital care for their medicines, products and therapies must be made as easy as possible. This is exactly what XO Life is pursuing with its meta-platform access."
"We are very pleased to welcome Dr. Jochen Hurlebaus to our team," says Friderike Bruchmann, Co-Founder & CEO of XO Life. "His many years of experience and his vision will help us to further develop our platform and expand globally. We are convinced that his contribution will be crucial to realize our mission and revolutionize digital healthcare for patients, professionals and manufacturers."
About XO Life
XO Life has created a globally unique meta-platform, the ImpactMonitor™ platform, for digital product and therapy support for patients. Patients are accompanied during their product application or therapy with verified medical and health-relevant content, record their health and therapy progress, receive personalized insights and medical support from experts, and can exchange information with other patients.
Manufacturers create their own product and therapy areas on the ImpactMonitor™ platform and offer them to their patients with their own branding, content, questions and services. Through personalized information and continuous support during therapies, manufacturers make an important contribution to the success of therapy, treatment adherence and application safety for patients.
XO Life is one of the great beacons of hope in the healthcare sector and is one of the leading digital health start-ups in Germany and Europe. In March 2023, XO Life was nominated for the Digital Award by the Federal Ministry of Economics and Climate Protection as one of 10 start-ups from various economic sectors.
XO Life works with global market leaders, SMEs and rare disease manufacturers in more than 30 indications. User engagement on the platform is 10x higher than in an average digital health app and last year alone over 120,000 medical questions were answered by patients. The ImpactMonitor™ platform is now available in all European countries and languages.
Recommended links
Website: www.xo-life.com
LinkedIn: https://www.linkedin.com/company/xo-life
Would you like to find out more or are you interested in XO Life?
Get in touch now, get a demo or answer individual questions in a personal conversation.
Discover even more news
Glenmark launcht eigenen Bereich für Malaria-Prophylaxe und -Therapie auf der ImpactMonitor™-Plattform von XO Life
Dr. Gustav Klein and XO Life: Digital therapy support for users of Gastritol® Liquid for gastrointestinal complaints
